70 For many women with early breast cancer, surgery is effective but life-altering. New five-year data from the National Institutes for Quantum Science and Technology (QST) suggest that a precisely targeted, high-energy particle therapy may allow some patients to avoid surgery without compromising oncological outcomes. In a single-centre, prospective phase II study, carbon-ion radiotherapy provided durable tumour control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The study was published online on 24th October 2025 in the International Journal of Radiation Oncology Biology Physics. The societal impact is clear: expanding access to a non-surgical, organ-sparing treatment option has the potential to improve quality of life, particularly for older adults, patients with comorbidities, or those who wish to avoid mastectomy or lumpectomy. At five years, local control and disease-free survival rates were both 92%, overall survival was 100%, and no grade 2 or higher toxicities were observed. Most patients experienced only mild, transient skin reactions. Cosmetic outcomes were rated as excellent in all but one case, which later required mastectomy because of local recurrence. “Carbon-ion radiotherapy combines high biological effectiveness with highly precise dose delivery,” said Noriyuki Okonogi, MD, PhD, QST Hospital. “In selected patients with small, estrogen receptor–positive, HER2-negative tumours, we observed complete responses in all cases, with sustained tumour control and minimal treatment-related burden.” The research team treated twelve women aged 60 years or older with stage I invasive ductal carcinoma. Tumours were ≤2 cm in diameter. All patients received carbon-ion radiotherapy at a total dose of 60 Gy (RBE) delivered in four fractions over one week, followed by standard adjuvant aromatase inhibitor therapy for at least five years. Follow-up included serial MRI examinations until complete response—typically observed at around 12 months—followed by semiannual imaging thereafter. One in-field recurrence occurred in a tumour with a high Ki-67 index, underscoring the importance of biological factors in patient selection. “The sharp dose conformity enabled by the Bragg peak allows us to spare healthy tissue while delivering ablative radiation to the tumour,” said Kumiko Karasawa, MD, PhD, QST Hospital. “The absence of clinically significant toxicity, together with preservation of breast appearance, is central to patients’ well-being and daily quality of life.” Kazutoshi Murata, MD, PhD, section manager, urinary and reproductive oncology section, Department of Diagnostic Radiology and Radiation Oncology, QST Hospital, highlighted the broader implications: “Our findings indicate that carbon-ion radiotherapy can provide a new treatment pathway for patients who value both oncological safety and quality of life. As technology advances, we aim to expand access to this approach, thereby reducing the physical and emotional burden associated with surgery.” This trial highlights how the unique physical and biological properties of particle therapy—namely high linear energy transfer and sharply confined dose deposition—can translate into tangible clinical benefits. Compared with photon-based ablative regimens, which have reported higher rates of moderate skin toxicity, carbon-ion therapy in this cohort achieved comparable tumour control with fewer adverse effects. The authors call for multi-institutional, controlled trials to validate these findings and to further refine biomarkers such as Ki-67 for optimal patient selection. Looking ahead, the team envisions broader clinical availability within the next five years through expanded trials and dedicated treatment pathways for non-surgical candidates. Over the next decade, carbon-ion radiotherapy protocols for breast cancer could be incorporated into standard treatment algorithms for well-defined patient subgroups—reducing surgical interventions while preserving body image and maintaining oncological safety.